In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities! #EULAR2021 @Rheumnow #OP0098 https://t.co/pSrr1dzKFP

Double hit”: #OP0015 Phase IIA ABBV-3373 (Adalimumab linked to GC receptor modulator GRM) vs. PBO and historic ADA show promising results with a satisfactory safety profile compared to ADA. A potential new IV drug in RA! #EULAR2021 @Rheumnow https://t.co/mqLtXx9zBI

Acute Coronary Syndrom incidence in > 24,000 RA from Nordic registers followed up to 5 yrs = 5.5/1000 pyrs. After 5yrs RTX show > risk of ACS compared to ETA. In patient with >= 2 previous DMARDs ABA, INF and RTX > risk of ACS compared to ETA. #EULAR2021 @Rheumnow #OP0114 https://t.co/MjW9LI2cjt

Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest? #EULAR2021 @Rheumnow #OP0116

Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up. Tight and early disease control reduces CV burden! #EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf

In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts. #EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz

MTX or ETA which one withdraw first? @RADoctor SEAM-RA trial: PROs following withdrawal of MTX or ETN in RA patients with sustained SDAI remission receiving combination ETN+MTX. ETA > MTX for maintaining SDAI remission at W48 (49.5%-28.7% P=0.004) #EULAR2021 @Rheumnow #OP0118 https://t.co/MSOclXGMEK

Rheum alliance trainee survey (n=302): 87-96% report negative impact of COVID19 on Rheumatology training: -outpatient clinics (79%) -inpatient consultations (59%) -formal teaching (55%) -procedures (53%) and -ultrasonography (36%) #POS0051 @RheumNow #EULAR2021 @kristenyoung

Can we predict pre-clinical RA-ILD? @Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%) #POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO

Curious to find out the answer?https://t.co/cXjUeQAwHD #EULAR2021 @RheumNow #OP0012 https://t.co/7q5yZLD96v

• https://twitter.com/AurelieRheumo/status/1400158204148002817
• https://twitter.com/AurelieRheumo/status/1400112099838332933

Very informative #EULAR2021 WIN session on MIS-C @EULAR_org 👉 Steroids early 👉 IVIg in all 👉 anticoagulant use remains variable #Coronary aneurysms ✅ occur during acute phase in MIS-C and improve with treatment ✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK

Does skin #lupus respond differently to rituximab?Dr Carter @LucyCarter6 reported 75% cutaneous response rate but overall non-response to tx was caused by skin domain. Interestingly, resistant skin post-tx was associated with low baseline #IFN scores #EULAR2021 #OP0134 @RheumNow https://t.co/JdtwdwNR4Z

Can machine learning show JAKi effects for safety? Off target binding predicted in #tofacitinib 58, #baricitinib 41 but NO pathway for thrombosis or viral infection. Could have repurposing for + effects on lung vasculature & antifibrotic effects POS0091 #EULAR2021 @RheumNow

MACE events with #JAKi is as clear as mud! You voted >50% NOT Sure 1/3 only some Jakis vs MACE in #TNFi! Dunno #EULAR2021 @RheumNow @eular_org https://t.co/vWUgKSwAap

Does anti-CD20 mAb still have a place in #Sjogren? Dr Pontarini analysed salivary gland biopsy from TRACTISS and reported beneficial effects of RTX in⬇️regulating genes involved in immune cell recruitment, activation and organisation in ectopic GC #EULAR2021 #OP0136 @RheumNow https://t.co/FRUvo4JxTx